<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00769106</url>
  </required_header>
  <id_info>
    <org_study_id>SunYat-senU 5010</org_study_id>
    <nct_id>NCT00769106</nct_id>
  </id_info>
  <brief_title>Study of Cytokine-induced Killer Cell (CIK) Treatment in Patients After Resection of Liver Cancer</brief_title>
  <acronym>HCC-CIK</acronym>
  <official_title>A Randomized Controlled Study of Cytokine-induced Killer Cell (CIK) Treatment in Patients With Hepatocellular Carcinoma Who Underwent Radical Resection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study hypothesis:&#xD;
&#xD;
      The recurrence rate of HCC patients after radical resection is about 60-70%. This study is&#xD;
      based on the hypothesis that CIK treatment could decrease the recurrence rate by 15% to 20%.&#xD;
&#xD;
      Abstract:&#xD;
&#xD;
      This is a randomized controlled study. About 200 patients with hepatocellular carcinoma who&#xD;
      underwent radical resection will be included. The patients will be randomized to group A&#xD;
      (receive CIK treatment) or group B (just regularly follow up) without any anti-cancer&#xD;
      treatment after resection of HCC, and the randomize ratio will be 1:1.&#xD;
&#xD;
      Study treatment:&#xD;
&#xD;
      Patients in group A will receive 4 cycles of CIK treatments within 3 months after their liver&#xD;
      resection. Patients in group B will have no anti-cancer therapy. Anti-virus and other&#xD;
      supportive therapies are available in both groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to recurrence (TTR)</measure>
    <time_frame>month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory findings</measure>
    <time_frame>every 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs and SAEs</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>B (control group)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>regular treatment and follow up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A (CIK group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cytokine-induced killer cell treatment plus regular treatment and follow up</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cytokine-induced killer cell (CIK) treatment</intervention_name>
    <description>cytokine-induced killer cell treatment every two weeks, for 4 cycles</description>
    <arm_group_label>A (CIK group)</arm_group_label>
    <other_name>CIK</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Male or female patients &gt; 18 years of age.&#xD;
&#xD;
          -  Without any prior anti-cancer therapy.&#xD;
&#xD;
          -  Patients who have a life expectancy of at least 12 weeks.&#xD;
&#xD;
          -  Patients already had radical resection of HCC.&#xD;
&#xD;
          -  Definition of radical resection in this study:&#xD;
&#xD;
          -  All tumors were moved out, with a clean resection margin.&#xD;
&#xD;
          -  Number of tumors &lt;= 3.&#xD;
&#xD;
          -  Without tumor invasion of the main trunk and first branch of the portal vein, or&#xD;
             hepatic duct, or hepatic vein.&#xD;
&#xD;
          -  No hepatic hilum lymphnode metastasis.&#xD;
&#xD;
          -  No distance metastasis.&#xD;
&#xD;
          -  Hepatocellular carcinoma with histological diagnose.&#xD;
&#xD;
          -  No major post-operative complication.&#xD;
&#xD;
          -  Patients who have an ECOG PS of 0, or 1.&#xD;
&#xD;
          -  Cirrhotic status of Child-Pugh class A only.&#xD;
&#xD;
          -  The following laboratory parameters:&#xD;
&#xD;
               -  Platelet count &gt;= 70 x 109/L&#xD;
&#xD;
               -  Hemoglobin &gt;= 8.5 g/dL&#xD;
&#xD;
               -  Albumin &gt;= 3.5 g/dL&#xD;
&#xD;
               -  Total bilirubin &lt;= 25umol/L&#xD;
&#xD;
               -  Alanine transaminase (ALT) and AST &lt;= 2.5 x upper limit of normal&#xD;
&#xD;
               -  Serum creatinine &lt;= 1.5 x the upper limit of normal&#xD;
&#xD;
               -  Prothrombin time (PT) &lt;= 3 seconds above control.&#xD;
&#xD;
               -  Patients who give written informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Previous or concurrent cancer that is distinct in primary site or histology from HCC.&#xD;
&#xD;
          -  History of cardiac disease.&#xD;
&#xD;
          -  Active clinically serious infections (&gt; grade 2 National Cancer Institute [NCI]-Common&#xD;
             Terminology Criteria for Adverse Events [CTCAE] version 3.0)&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Known Central Nervous System tumors including metastatic brain disease.&#xD;
&#xD;
          -  Patients with clinically significant gastrointestinal bleeding within 30 days prior to&#xD;
             study entry.&#xD;
&#xD;
          -  History of organ allograft.&#xD;
&#xD;
          -  Known or suspected allergy to the investigational agent or any agent given in&#xD;
             association with this trial.&#xD;
&#xD;
          -  Pregnant or breast-feeding patients.&#xD;
&#xD;
          -  Any condition that is unstable or which could jeopardize the safety of the patient and&#xD;
             his/her compliance in the study.&#xD;
&#xD;
        Excluded therapies and medications, previous and concomitant:&#xD;
&#xD;
          -  Prior use of any anti-cancer treatment for HCC, eg. chemotherapy, radiotherapy.&#xD;
&#xD;
          -  Antiviral treatment is allowed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin-qing Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>October 7, 2008</study_first_submitted>
  <study_first_submitted_qc>October 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2008</study_first_posted>
  <last_update_submitted>April 13, 2016</last_update_submitted>
  <last_update_submitted_qc>April 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>LI Sheng-ping</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>recurrent</keyword>
  <keyword>cytokine-induced killer cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

